| Species |
Mouse |
| Protein Construction |
TFF1 (Gln22-Phe87)_x000D_
Accession # Q08423 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
34 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 38-42 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Breast cancer (BC) is the most common cancer in women and the second leading cause of their cancer death. Establishing an accurate BC prognosis is very difficult because of its heterogeneity. Elevated TFF1 levels in serum were associated with development of BC, TFF1 expression was upregulated in BC compared to the healthy breast tissue.That expression of TFF1 was related to ER status of BC and that expression of TFF1 was lower in TNBC than in non-TNBC. |
| Synonyms |
Trefoil factor 1; Bcei; BCEI; D21S21; HP1.A; HPS2; pNR-2; Polypeptide P1.A; PS2; TFF1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
